GT Biopharma (GTBP) Competitors $2.04 +0.04 (+2.00%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.06 +0.02 (+0.98%) As of 07/16/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. DARE, NRSN, MIRA, NNVC, FBLG, TPST, ALXO, QTTB, CVKD, and TENXShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Dare Bioscience (DARE), NeuroSense Therapeutics (NRSN), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), FibroBiologics (FBLG), Tempest Therapeutics (TPST), ALX Oncology (ALXO), Q32 Bio (QTTB), Cadrenal Therapeutics (CVKD), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Its Competitors Dare Bioscience NeuroSense Therapeutics MIRA Pharmaceuticals NanoViricides FibroBiologics Tempest Therapeutics ALX Oncology Q32 Bio Cadrenal Therapeutics Tenax Therapeutics GT Biopharma (NASDAQ:GTBP) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Which has more volatility and risk, GTBP or DARE? GT Biopharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Which has preferable earnings and valuation, GTBP or DARE? Dare Bioscience has higher revenue and earnings than GT Biopharma. Dare Bioscience is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$13.16M-$5.69-0.36Dare Bioscience$10K2,318.70-$4.05M-$0.17-15.41 Does the media refer more to GTBP or DARE? In the previous week, Dare Bioscience had 7 more articles in the media than GT Biopharma. MarketBeat recorded 8 mentions for Dare Bioscience and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.91 beat Dare Bioscience's score of 0.85 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Very Positive Dare Bioscience Positive Do analysts rate GTBP or DARE? GT Biopharma currently has a consensus target price of $11.00, suggesting a potential upside of 439.22%. Dare Bioscience has a consensus target price of $12.00, suggesting a potential upside of 358.02%. Given GT Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe GT Biopharma is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is GTBP or DARE more profitable? Dare Bioscience's return on equity of 0.00% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -1,033.08% -223.20% Dare Bioscience N/A N/A -8.14% Do insiders and institutionals have more ownership in GTBP or DARE? 8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 3.4% of GT Biopharma shares are owned by insiders. Comparatively, 4.0% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryGT Biopharma and Dare Bioscience tied by winning 7 of the 14 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.55M$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.3620.3628.1219.69Price / SalesN/A298.74439.46100.25Price / CashN/A42.3835.5357.53Price / Book-2.727.768.235.67Net Income-$13.16M-$55.11M$3.23B$257.51M7 Day Performance-10.92%0.19%-0.52%-0.16%1 Month Performance-27.14%10.80%6.71%9.89%1 Year Performance-26.09%-0.68%27.10%15.08% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma2.2306 of 5 stars$2.04+2.0%$11.00+439.2%-28.2%$6.55MN/A-0.368Positive NewsGap UpDAREDare Bioscience1.8401 of 5 stars$3.09+22.6%$12.00+288.3%-22.9%$27.35M$10K-18.1830High Trading VolumeNRSNNeuroSense Therapeutics2.4757 of 5 stars$2.00-3.4%$14.00+600.0%+131.1%$27.33MN/A-3.7010MIRAMIRA Pharmaceuticals2.454 of 5 stars$1.54+20.3%$14.00+809.1%+130.9%$26.06MN/A-3.022High Trading VolumeNNVCNanoViricides0.361 of 5 stars$1.60+14.7%N/A-21.6%$25.72MN/A-2.2220News CoverageHigh Trading VolumeFBLGFibroBiologics3.6404 of 5 stars$0.64+1.7%$13.00+1,931.3%-86.4%$25.40MN/A-3.0510TPSTTempest Therapeutics2.3677 of 5 stars$6.90-0.7%$30.00+334.8%-76.9%$25.39MN/A-0.3820Positive NewsALXOALX Oncology3.587 of 5 stars$0.47-2.8%$3.30+603.9%-94.3%$25.03MN/A-0.1940QTTBQ32 Bio2.6965 of 5 stars$2.03-23.7%$12.17+499.3%-89.6%$24.77M$1.16M-0.4139High Trading VolumeCVKDCadrenal Therapeutics2.9285 of 5 stars$12.50-3.3%$32.00+156.0%N/A$24.59MN/A-1.354Positive NewsGap DownTENXTenax Therapeutics1.6669 of 5 stars$5.90+1.7%$17.50+196.6%+70.6%$24.47MN/A-2.389Positive News Related Companies and Tools Related Companies Dare Bioscience Alternatives NeuroSense Therapeutics Alternatives MIRA Pharmaceuticals Alternatives NanoViricides Alternatives FibroBiologics Alternatives Tempest Therapeutics Alternatives ALX Oncology Alternatives Q32 Bio Alternatives Cadrenal Therapeutics Alternatives Tenax Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTBP Stock Alerts